Mostra i principali dati dell'item
dc.contributor.author | Vittori, Angelica | |
dc.contributor.author | Orth, Michael | |
dc.contributor.author | Roos, Raymund A. C. | |
dc.contributor.author | Outeiro, Tiago F. | |
dc.contributor.author | Giorgini, Flaviano | |
dc.contributor.author | Hollox, Edward J. | |
dc.contributor.author | Cubo Delgado, Esther | |
dc.contributor.author | REGISTRY investigators of the European Huntington's Disease Network | |
dc.date.accessioned | 2024-03-07T08:22:58Z | |
dc.date.available | 2024-03-07T08:22:58Z | |
dc.date.issued | 2013 | |
dc.identifier.issn | 1879-6397 | |
dc.identifier.uri | http://hdl.handle.net/10259/8769 | |
dc.description.abstract | Huntington's disease (HD) is an autosomal dominant neurodegenerative disorder caused by the abnormal expansion of a CAG triplet repeat tract in the huntingtin gene. While the length of this CAG expansion is the major determinant of the age of onset (AO), other genetic factors have also been shown to play a modulatory role. Recent evidence suggests that neuroinflammation is a pivotal factor in the pathogenesis of HD, and that targeting this process may have important therapeutic ramifications. The human β-defensin 2 (hBD2) – encoded by DEFB4 – is an antimicrobial peptide that exhibits inducible expression in astrocytes during inflammation and is an important regulator of innate and adaptive immune response. Therefore, DEFB4 may contribute to the neuroinflammatory processes observed in HD. | en |
dc.description.sponsorship | The authors thank contributors to the EHDN Registry study, listed in Appendix 1. AV is supported by Fundac¸ao para Ci ˜ enci ˆ aeaTecnologia (SFRH/ BD/4764/2008). TFO was supported by an EMBO Installation Grant and a Marie Curie International Reintegration Grant (Neurofold). FG was supported by a New Investigator Research Grant from the Medical Research Council (G0700090). EJH was supported by a New Investigator Research Grant from the Medical Research Council (GO801123). | en |
dc.format.mimetype | application/pdf | |
dc.language.iso | eng | es |
dc.publisher | IOS Press | en |
dc.relation.ispartof | Journal of Huntington's Disease. 2013, V. 2, n. 1, p. 107-124 | en |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.subject | Genetic modifier | en |
dc.subject | Copy number variation | en |
dc.subject | Inflammation | en |
dc.subject.other | Sistema nervioso-Enfermedades | es |
dc.subject.other | Nervous system-Diseases | en |
dc.subject.other | Medicina | es |
dc.subject.other | Medicine | en |
dc.title | β-Defensin Genomic Copy Number Does Not Influence the Age of Onset in Huntington's Disease | en |
dc.type | info:eu-repo/semantics/article | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.relation.publisherversion | https://content.iospress.com/articles/journal-of-huntingtons-disease/jhd130047 | es |
dc.identifier.doi | 10.3233/JHD-130047 | |
dc.journal.title | Journal of Huntington's Disease | en |
dc.volume.number | 2 | es |
dc.issue.number | 1 | es |
dc.page.initial | 107 | es |
dc.page.final | 124 | es |
dc.type.hasVersion | info:eu-repo/semantics/publishedVersion | es |